Combination of brimonidine timolol for topical ophthalmic use

Details Combination of brimonidine timolol for topical ophthalmic use Combination of brimonidine timolol for topical ophthalmic use

2006-04-18

2006-04-18

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S398000, C514S397000, C514S236200

Reexamination Certificate

active

07030149

ABSTRACT:
Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4195085 (1980-03-01), Stone
patent: 4861760 (1989-08-01), Mazuel et al.
patent: 4910225 (1990-03-01), Ogawa et al.
patent: 5021410 (1991-06-01), Burke
patent: 5290781 (1994-03-01), Espino et al.
patent: 5795913 (1998-08-01), Lehmussaari et al.
patent: 5827862 (1998-10-01), Yamamura et al.
patent: 5856329 (1999-01-01), Wheeler et al.
patent: 6159458 (2000-12-01), Bowman et al.
patent: 6174524 (2001-01-01), Bawa et al.
patent: 6194415 (2001-02-01), Wheeler et al.
patent: 6248741 (2001-06-01), Wheeler et al.
patent: 6316441 (2001-11-01), Dean et al.
patent: 6410045 (2002-06-01), Schultz et al.
patent: 6441047 (2002-08-01), DeSantis, Jr.
patent: 6562873 (2003-05-01), Olejnik et al.
patent: 6627210 (2003-09-01), Olejnik et al.
“Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy”, Stewart et al., Acta Opthalmologica Scandinavica, 2002, 80(3), 277-281.
“Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination”, Larsson, Lillinger, Archives of Ophthalmology, 2001, 119(4), 492-495.
“The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma”, Yuksel et all, Ophthalmologica, 1999, 213(4), 228-233.
“A short term study of the additive effect of timolol and brimonidine on intraocular pressure”, Arici et al., Eye, 2002, vol. 16.No. 1., pp. 39-43.
Sall et al, IOVS, 2001k, vol. 42, No. 4, pp. S822.
“Clinical Experience with Brimonidine 0.2% and Timolol 0.5% in Glaucoma and Ocular Hypertension”, Schuman, Survey of Ophthalmology, 1996, 41, suppl 1 S27-37.
“Cardiovascular effects of timolol, brimonidine and brimonidine/timolol in combination”, Jackson et al., IOVS, vol. 42, No. 4, pp. S418.
“Aqueous humor flow in normal human eyes treated with brimonidine and timolol., alone in combination”, Larsson, IOVS, 1999, vol. 40, No. 4, pp. S515.
Copy of Electronic Data showing the receival of Archives of Ophtalmology, vol. 121 No. 7, Apr. 2001.
“Prospective Survey of Adverse Reactions to Topical Antiglaucoma Medications in a Hospital Population”, Bhatt et al., Eye Advance Online Publication Aug. 6, 2004, abstract.
Drug Information Brochure on Alphagan, Allergan, 2001.
Drug information Brochure on Timoptic, MSD., 2001.
Hommer, A.B., et al.,Efficacy and Safety of Unoprostone, Dorzolamide, and Brimonidine in Adjunctive Therapy to Timolol in Pateitnts with primary open-angle glaucoma and ocular hypertension, Investigative Ophthalmology & Visual Science, vol. 42, No. 4, Supp. Mar. 15, 2001, p. 554.
Hoyng, P.F., et al.,Pharmacological Therapy of glaucoma, Drugs, vol. 59, No. 3, Mar. 2000 pp. 411-434.
Stewart, W.C.,Perspectives in the medical treatment of glaucoma, Current Opinion in Ophthalmology, vol. 10, No. 2, Apr. 1999, pp. 99-109.
Wang, R.F., et al.,Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes, J. of Glaucoma 9:458-62.
Goni et al, “Comparison of Fixed-Combination Brimonidine and Timolol With Concomitant Use of the Individual Components in Glaucoma and Ocular Hypertension: Achievement of Clinically Relevant IOP Reductions”, Mar. 1, 2005, Allergan Manuscript/Abstratct/Presentation Form, 23 pages.
Craven et al, Efficacy and Safety of the IOP-Lowering Fixed Combination Brimonidine 0.2%/Timolol 0.5%, M200510403E.1.doc, one page, 2005.

Affiliated with

Also associated with

Rating

Combination of brimonidine timolol for topical ophthalmic use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination of brimonidine timolol for topical ophthalmic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of brimonidine timolol for topical ophthalmic use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3572560